US EditionUS and UK agree zero-tariffs on pharmaceuticals
The UK will increase NHS medicine spending by 25% and raise cost-effectiveness thresholds as the US agrees to zero tariffs on British pharmaceutical imports.
- On Monday , the United States and United Kingdom announced a deal exempting UK pharmaceuticals from US import taxes in exchange for increased UK medicine spending, USTR Greer said.
- After months of escalation, tariff threats and investment withdrawals prompted urgent talks as the Trump administration threatened 100% tariffs and major firms including AstraZeneca, GSK and Merck paused UK projects, while US ambassador Warren Stephens warned earlier this month.
- The UK agreed to specific pricing changes including raising the NICE threshold to �35,000 and lowering the NHS rebate rate to 15% in 2026, while the NHS will spend 25% more on new treatments.
- AstraZeneca and GSK's US commitments suggest the deal will redirect major investments, with $50bn and $30bn pledges, protecting UK pharmaceutical exports valued at 17.4%.
- Months of talks culminated in a package that ties zero US tariffs to UK changes in drug‑pricing policy and secured three‑year 0% tariff protection for UK medicine exports, led by Varun Chandra and Lord Vallance.
98 Articles
98 Articles
U.K. and U.S. Agree on Zero-Tariff Deal on Pharmaceuticals
(MedPage Today) -- The U.K. has secured a 0% tariff rate for all U.K. medicines exported to the U.S. for at least 3 years, officials said Monday, in return for the U.K. spending more on new medicines. Under the deal, the U.S. agreed to exempt...
The United States Government has reached a principle in agreement with the United Kingdom on pharmaceutical prices under which Washington will exempt imports of these products of British origin from tariffs, while London is committed to raising the spending of the National Health Service (NHS) on medicines and increasing the net price paid for new treatments by 25%.
New trade deal pushes UK to increase drug spending to avoid Trump tariffs
The United States and the United Kingdom announced a high-level trade deal Monday that would exempt U.K. pharmaceuticals from U.S.-imposed tariffs in exchange for Britain paying more for medicines. President Trump has long complained that wealthy nations don’t pay enough for prescription drugs, forcing the U.S. to shoulder more of the price burden. The announcement marks a further development in Trump’s quest to tie domestic prices to those…
UK wins zero tariff deal with US on drugs but will pay more for medicines
The United States and Britain announced a deal today to secure zero tariffs on UK pharmaceutical products and medical technology in return for Britain spending more on medicines and overhauling how it values drugs.
Coverage Details
Bias Distribution
- 54% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
